Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Altimmune, a biopharmaceutical company based in Maryland, has announced plans to test an investigational drug based on GLP-1 for the treatment of alcohol use disorder. This drug is also being studied by Eli Lilly and Novo Nordisk for alcohol- and liver-related conditions. Altimmune joins these companies in exploring the potential of GLP-1 agonists for this indication. The recommendations for flu vaccine usage were recently made by the FDA in a closed session involving representatives from CBER, the CDC, and the Department of Defense.In other news, Pfizer has ended a trial for an early-stage cancer drug, Sutro has cut half of its staff and deprioritized a drug for ovarian cancer, and Pliant has implemented a poison pill strategy. Additionally, Wacker Biotech is offering services for advanced therapies, including process development and production of DNA and RNA. The biotech industry continues to see shifts and developments in various companies and research areas.